Two groups have come together to develop and invest in healthcare in Singapore. Germany-based B Braun and Trendlines Group have signed a cooperation agreement to jointly invest in Trendlines Medical Singapore (TMS), which is a platform to invest in and incubate early-stage healthcare companies.
Both parties will be appointing members to Trendlines Medical Singapore’s board of directors and investment committee, and B. Braun will advise on market needs and technical and commercial matters. President (APAC) and a member of the B Braun management board Anna Maria Braun, and Boris Hofmann, director of business development of B Braun’s Aesculap division, are joining the TMS board of directors. Todd Dollinger, chairman and CEO of Trendlines, will be the chairman of TMS.
Trendlines will be holding the majority of shares 79.26 per cent while B Braun will take a minority stake of 20.74 per cent in TMS.
Trendlines is a Singapore listed company operating in Israel. TMS is an innovation commercialization company and Trendlines’ first incubator outside of Israel. They invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies. As intensely hands-on investors, they are involved in all aspects of our portfolio companies from technology development to business building. Commenting on the establishment of Trendlines Medical Singapore, D. Todd Dollinger, Chairman and CEO of Trendlines, said,
The combination of Trendlines experience in business incubation, B. Braun’s knowledge and industry insights and financial strength, gives strong support to the launch of Trendlines Medical Singapore.
B Braun will support the commercialization of TMS’s portfolio companies by providing medtech-related expertise, such as regulations, medical and scientific affairs, and marketing and sales. Mr Dollinger said in September when the joint investment with B Braun was unveiled, that though its focus is in medtech, TMS will not rule out investing in other tech types. With over 56,000 employees in 64 countries, B. Braun is one of the world’s leading manufacturers of medical devices and pharmaceutical products and services.
Mr Dollinger said in September when the joint investment with B Braun was unveiled, that though its focus is in medtech, TMS will not rule out investing in other tech types. With over 56,000 employees in 64 countries, B. Braun is one of the world’s leading manufacturers of medical devices and pharmaceutical products and services.
